1. Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate
- Author
-
Zhou Wang, Laura E. Pascal, Jianhua Luo, Ricardo Z. N. Vêncio, Bruna R. Correa, and Fei Su
- Subjects
MAPK/ERK pathway ,Original Paper ,Cancer Research ,Microarray analysis techniques ,NEOPLASIAS PROSTÁTICAS ,Biology ,medicine.disease_cause ,medicine.disease ,Cell biology ,Androgen receptor ,Gene expression profiling ,Prostate cancer ,Oncology ,Immunology ,medicine ,Signal transduction ,Carcinogenesis ,PI3K/AKT/mTOR pathway - Abstract
U19/EAF2 is regulated by androgens in the prostate and capable of regulating transcriptional elongation of RNA Pol II via interaction with the ELL family proteins. Inactivation of U19/EAF2 induces tumorigenesis in multiple organs; however the mechanism of U19/EAF2 tumor suppression remains unclear. To elucidate potential mechanisms of U19/EAF2 action, we performed cDNA microarray analysis and identified 164 mRNA transcripts regulated by U19/EAF2 in the mouse ventral prostate. Bioinformatics analysis indicated that U19/EAF2 knockout activates the RAS-BRAF-ERK signaling pathway, which is known to play important roles in carcinogenesis. qPCR verified increased expression of BRAF mRNA, and immunostaining and Western blot analysis demonstrated increased expression of p-ERK at the protein level suggested U19/EAF2 knockout activates this important pathway. These findings indicate that loss of EAF2 up-regulates transcription of RAS cascade genes including Grb2, PI3K, and BRAF, leading to elevated p-ERK levels, which may represent a major functional role of U19/EAF2 in the prostate. Furthermore, these observations suggest that U19/EAF2 is a key player in crosstalk between androgen receptor and the RAS-BRAF-ERK signaling pathway.
- Published
- 2013
- Full Text
- View/download PDF